Combo Plus
临床试验

COMBO Plus

带内皮祖细胞（EPC）捕获技术的COMBO Plus双疗法支架已在多个随机研究和注册登记中进行临床评估，评估证实其对广大患者安全有效，且必要时患者可灵活选择短期双联抗血小板治疗(DAPT).

随机试验 注册登记试验 超过 9,600 名 受试者参加了 随机对照试验和 全人群注册登记试验

Prospective, multicentre, all-comers, European registry. NCT01874002

Single-center study with serial OCT assessment of COMBO’s healing profile. NCT01274234, NCT01756807, NCT02263313

Prospective, multicenter, all-comers’ registry with patients from Asia and Europe. NCT02183454

Prospective, single-center, AMI Singapore registry.

Prospective, single-center, randomized study in STEMI patients assessing endothelial function response after stenting. NCT04202172

Prospective multicentre, all comers, randomized trial. NCT03216733

Prospective, multicentre, randomized study for China approval. NCT02542007

Prospective, multicentre, randomized study in acute coronary syndrome patients with shortened DAPT NCT02118870

Prospective, multicentre randomized trial for Japanese approval & US feasibility. NCT02073565

Prospective, multicentre, randomized OCT study. NCT01405287

Prospective, multicentre randomized first-in-man study for CE approval. NCT00967902

G-70-1096